Welcome to CSNpharm! For Research Use Only!
Home
+1-708-781-1677
sales@csnpharm.com
HER2
| Cat. No. | Product Name | CAS No. | Information |
|---|---|---|---|
| CSN12170 | Tyrphostin AG 879 | 148741-30-4 | Tyrphostin AG 879 potently inhibits HER2ErbB2 with IC50 of 1 M 100- and 500-fold higher selective to ErbB2 than PDGFR and EGFR |
| CSN16247 | TAK-285 | 871026-44-7 | TAK-285 is a dual HER2 and EGFR HER1 inhibitor with IC50 of 17 nM and 23 nM 10-fold selectivity for HER12 than HER4 less potent to MEK15 c-Met Aurora B Lck CSK etc |
| CSN15811 | AZD8931 | 848942-61-0 | Sapitinib is a reversible ATP competitive inhibitor of EGFR ErbB2 and ErbB3 with IC50 of 4 nM 3 nM and 4 nM respectively |
| CSN20576 | Neratinib Maleate | 915942-22-2 | Neratinib maleate is an orally available irreversible tyrosine kinase inhibitor with IC50 of 59 nM and 92 nM for HER2 and EGFR respectively |
| CSN12420 | Neratinib | 698387-09-6 | Neratinib is an orally available irreversible tyrosine kinase inhibitor with IC50 of 59 nM and 92 nM for HER2 and EGFR respectively |
| CSN11482 | Mubritinib | 366017-09-6 | Mubritinib is a potent and selective inhibitor of HER2ErbB2 with IC50 of 6 nM with no inhibition on EGFR FGFR PDGFR and etc |
| CSN11269 | Lapatinib Ditosylate | 388082-77-7 | Lapatinib ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 108 and 92 nM respectively |
| CSN18606 | Irbinitinib | 937263-43-9 | Irbinitinib is a potent and selective HER2 inhibitor with IC50 of 8 nM, equipotent against truncated p95-HER2, 500-fold selective for HER2 versus EGFR. |
| CSN12702 | CP-724714 (Random Configuration) | 537705-08-1 | CP-724714 is a potent selective inhibitor of HER2ErbB2 with IC50 of 10 nM 640-fold selectivity against EGFR InsR IRG-1R PDGFR VEGFR2 Abl Src c-Met etc in cell-free assays |
| CSN18252 | CP-724714 | 383432-38-0 | CP-724714 is a potent selective inhibitor of HER2ErbB2 with IC50 of 10 nM 640-fold selectivity against EGFR InsR IRG-1R PDGFR VEGFR2 Abl Src c-Met etc |
+1-708-781-1677
+1-708-286-6026
sales@csnpharm.com
